Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    IntReALL 2010 SR
Previous Study | Return to List | Next Study

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01802814
Recruitment Status : Recruiting
First Posted : March 1, 2013
Last Update Posted : May 30, 2018
Sponsor:
Collaborators:
Australian and New Zealand Children's Haematology/Oncology Group
St. Anna Kinderkrebsforschung (Co-Sponsor Austria)
European Organisation for Research and Treatment of Cancer - EORTC
University Hospital Motol (Co-Sponsor Czech Republic)
Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen)
Turku University (Co-Sponsor Finland)
Centre Hospitalier Universitaire de Nice
Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)
Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)
Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy)
National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan)
Prinses Máxima Centrum (Co-Sponsor Netherlands)
Oslo University Hospital (Co-Sponsor Oslo)
Medical University of Wroclaw (Co-Sponsor Poland)
Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa)
Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)
University Hospital Stockholm (Co-Sponsor Sweden)
University Children's Hospital Zurich (Co-Sponsor Switzerland)
Central Manchester University (Co-Sponsor UK)
Information provided by (Responsible Party):
PD Dr. Arend von Stackelberg, Charite University, Berlin, Germany

Tracking Information
First Submitted Date  ICMJE February 18, 2013
First Posted Date  ICMJE March 1, 2013
Last Update Posted Date May 30, 2018
Actual Study Start Date  ICMJE May 2014
Estimated Primary Completion Date May 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 25, 2018)
  • SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1) [ Time Frame: Up to 9 years ]
    SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1): 10% pEFS superiority of arm B above a 65% pEFS at 4 years of arm A
  • SR consolidation +/- epratuzumab (randomisation 2) [ Time Frame: Up to 9 years ]
    SR consolidation +/- epratuzumab (randomisation 2): 10% pEFS superiority of the arm with epratuzumab above an expected 74% pEFS at 4 years of the standard arm
Original Primary Outcome Measures  ICMJE
 (submitted: February 28, 2013)
  • SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1) [ Time Frame: at 4 years of arm A ]
    SR induction/consolidation ALL-REZ BFM 2002 versus UK-ALL-R3 (randomisation 1): 10% pEFS superiority of arm B above a 65% pEFS at 4 years of arm A
  • SR consolidation +/- epratuzumab (randomisation 2) [ Time Frame: at 4 years of standard arm ]
    SR consolidation +/- epratuzumab (randomisation 2): 10% pEFS superiority of the arm with epratuzumab above an expected 74% pEFS at 4 years of the standard arm
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2018)
  • SR induction/consolidation [ Time Frame: Up to 9 years ]
    SR induction/consolidation: comparison of OS, toxicity, rate of CR2, and rate of MRD between treatment groups
  • SR consolidation +/- epratuzumab [ Time Frame: Up to 9 years ]
    SR consolidation +/- epratuzumab: comparison of OS, toxicity, MRD levels, rate of MRD and evaluation of pharmacokinetic parameters of Epratuzumab
Original Secondary Outcome Measures  ICMJE
 (submitted: February 28, 2013)
  • SR induction/consolidation [ Time Frame: year 7 ]
    SR induction/consolidation: comparison of OS, toxicity, rate of CR2, and rate of MRD between treatment groups
  • SR consolidation +/- epratuzumab [ Time Frame: year 7 ]
    SR consolidation +/- epratuzumab: comparison of OS, toxicity, MRD levels, rate of MRD and evaluation of pharmacokinetic parameters of Epratuzumab
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
Official Title  ICMJE International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Brief Summary The main goal of this study is to improve the outcome of children and adolescents with standard risk first relapsed acute lymphoblastic leukemia. Furthermore, goal is to set up a large international study group platform allowing for optimization of standard treatment strategies and integration of new agents.
Detailed Description

ALL is the most frequent malignancy in childhood and has favourable event-free and overall survival rates. About 15% of patients suffer relapse. At relapse prognosis is much inferior (about 50% survival) leukemic clones exhibit much more resistance to conventional chemotherapy. Patients with relapse require treatment intensification and different therapeutic strategies. At relapse, new targeted agents can provide the chance for better cure rates and need to be investigated in prospective controlled trials before they may be even eligible for frontline treatment strategies.

The IntReALL SR 2010 trial is designed to achieve 2 major aims: Establishment of the best available standard chemotherapy treatment. This is addressed with the randomization of the 2 best developed strategies for treatment of childhood relapsed ALL, the German ALL-REZ BFM 2002 Protocol with the Protocol II IDA arm, and the British ALL-R3 protocol with the mitoxantrone arm. This randomization allows confirming the feasibility of both protocols in a large variety of different countries and study groups with different frontline therapy strategies. As result from this trial a common standard chemotherapy for childhood relapsed ALL will be developed which can serve as backbone for investigation of the most attractive targeted new agents.

The 2nd aim is the investigation of the efficacy and tolerability of the humanized CD22 directed monoclonal antibody Epratuzumab, manufactured and provided by the company Immunomedics, US. The drug will be randomly added to the respective consolidation chemotherapy, using EFS as primary endpoint. Epratuzumab has been developed in adult rheumatology indications and in B-cell malignancies. A phase I and early phase II combination trial in childhood relapse ALL has been conducted and published by the Children's Oncology Group (COG), and results of an extended phase II trial have been recently presented at the ASH meeting (12/2011). The drug showed a very favourable safety profile as single drug and in combination with multidrug chemotherapy. Activity was moderate, the recent trial showed a significantly better elimination of minimal residual disease (MRD) in patients achieving a 2nd complete remission. This finding supports the strategy to use Epratuzumab in combination with consolidation chemotherapy after induction in patients having reduced the leukemia burden in the bone marrow to at least below 25%, most of them will be in 2nd complete remission. Epratuzumab will be given weekly at the established dose. Pharmacokinetics will be investigated in a reduced number of patients. The further treatment will be conventional intensive chemotherapy and maintenance therapy in patients with good MRD response after induction, or with allogeneic stem-cell transplantation (SCT) in those with insufficient MRD response. SCT will be considered as standard treatment element and will not lead to censoring of the patients of considered as endpoint. Epratuzumab is not licensed so far and the trial may add to the approval process in case.

Scientific advice for the trial has been requested at the FDA and the EMA. Both institutions have responded supportively. Concerns and recommendations of FDA and EMA have been addressed in the protocol and the corresponding statistical analysis plan.

The IntReALL SR 2010 trial will be financed within the FP7 project IntReALL 2010 supported by the European Commission. Within the project next to the SR trial a strategy for HR patients will be addressed, the establishment of harmonized diagnostic procedures, an international tumour bank and a comprehensive biologic/scientific programme will be set up, a web-based GCP conform database will be established, a comprehensive statistical strategy for both trials are established, and drug development in this indication will be promoted and organized from side of the disease experts in cooperation with the established academic structures ITCC (Innovative Therapies for Children with Cancer), the ENCCA project (European Network for Cancer in Children and Adolescents) and SIOPe (International Society for Pediatric Oncology Europe), the central authorities (EMA, FDA) and Industry. Parent organisation and former patients are integrated into and accompany the process.

Main aims of the IntReALL FP7 project are to establish a therapeutic platform for children with relapsed ALL in Europe and beyond and to give them access to the most promising new agents under academic control and free from commercial interests.

Randomized evidence for efficacy and tolerability of new drugs are demanded by competent authorities. These trials are conducted beyond the mostly palliative patient group eligible for phase I/II trials in curative indications. Treatment protocols for with curative indications need to be conducted in the best interests of the patients, ideally with an academic sponsor. The design should be driven by medical and scientific evidence and not by commercial interests as is the case in industry sponsored trials. This concept was acknowledged by the European Commission selecting the project for funding from many other powerful applications.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Lymphoblastic Leukemia (ALL)
Intervention  ICMJE
  • Drug: SR-A + Epratuzumab
    Other Name: Epratuzumab
  • Drug: SR-B + Epratuzumab
    Other Name: Epratuzumab
Study Arms  ICMJE
  • No Intervention: SR-A
    Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.
  • Active Comparator: SR-A + Epratuzumab
    Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab.
    Intervention: Drug: SR-A + Epratuzumab
  • No Intervention: SR-B
    Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab.
  • Active Comparator: SR-B + Epratuzumab
    Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab.
    Intervention: Drug: SR-B + Epratuzumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 28, 2013)
1242
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2023
Estimated Primary Completion Date May 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Morphologically confirmed diagnosis of 1st relapsed precursor B-cell or T-cell ALL
  • Children less than 18 years of age at inclusion
  • Meeting SR criteria: late isolated or late/early combined BCP BM relapse, any late/early isolated extramedullary relapse
  • Patient enrolled in a participating centre
  • Written informed consent
  • Start of treatment falling into the study period
  • No participation in other clinical trials 30 days prior to study enrolment that interfere with this protocol, except trials for primary ALL Inclusion criteria specific for the epratuzumab randomization
  • Precursor B-cell immunophenotype. A specific CD22 expression level is not required
  • M1 or M2 status of the bone marrow after induction

Exclusion Criteria:

  • BCR-ABL / t(9;22) positive ALL
  • Pregnancy or positive pregnancy test (urine sample positive for β-HCG > 10 U/l)
  • Sexually active adolescents not willing to use highly effective contraceptive method (pearl index <1) until 2 years after end of antileukemic therapy
  • Breast feeding
  • Relapse post allogeneic stem-cell transplantation
  • The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
  • No consent is given for saving and propagation of pseudonymized medical data for study reasons
  • Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders)
  • Karnovsky / Lansky score < 50%
  • Subjects unwilling or unable to comply with the study procedures
  • Subjects who are legally detained in an official institute
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Arend von Stackelberg, MD +49(0)30-450666 ext 833 arend.stackelberg@charite.de
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Czechia,   Denmark,   Finland,   France,   Germany,   Ireland,   Israel,   Italy,   Japan,   Netherlands,   Norway,   Poland,   Portugal,   Sweden,   Switzerland,   United Kingdom
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01802814
Other Study ID Numbers  ICMJE IntReALL SR 2010
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party PD Dr. Arend von Stackelberg, Charite University, Berlin, Germany
Study Sponsor  ICMJE Charite University, Berlin, Germany
Collaborators  ICMJE
  • Australian and New Zealand Children's Haematology/Oncology Group
  • St. Anna Kinderkrebsforschung (Co-Sponsor Austria)
  • European Organisation for Research and Treatment of Cancer - EORTC
  • University Hospital Motol (Co-Sponsor Czech Republic)
  • Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen)
  • Turku University (Co-Sponsor Finland)
  • Centre Hospitalier Universitaire de Nice
  • Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)
  • Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)
  • Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy)
  • National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan)
  • Prinses Máxima Centrum (Co-Sponsor Netherlands)
  • Oslo University Hospital (Co-Sponsor Oslo)
  • Medical University of Wroclaw (Co-Sponsor Poland)
  • Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa)
  • Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)
  • University Hospital Stockholm (Co-Sponsor Sweden)
  • University Children's Hospital Zurich (Co-Sponsor Switzerland)
  • Central Manchester University (Co-Sponsor UK)
Investigators  ICMJE
Principal Investigator: Arend von Stackelberg, MD University Hospital of Berlin - Charité
PRS Account Charite University, Berlin, Germany
Verification Date May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP